Vasohibin-1, a Negative Feedback Regulator of Angiogenesis, Ameliorates Renal Alterations in a Mouse Model of Diabetic Nephropathy by Nasu, Tatsuyo et al.
Vasohibin-1, a Negative Feedback Regulator of
Angiogenesis, Ameliorates Renal Alterations in a Mouse
Model of Diabetic Nephropathy
Tatsuyo Nasu,
1 Yohei Maeshima,
1 Masaru Kinomura,
1 Kumiko Hirokoshi-Kawahara,
1
Katsuyuki Tanabe,
1 Hitoshi Sugiyama,
1,2 Hikaru Sonoda,
3 Yasufumi Sato,
4 and Hirofumi Makino
1
OBJECTIVE—The involvement of proangiogenic factors such
as vascular endothelial growth factor as well as the therapeutic
efﬁcacy of angiogenesis inhibitors in early diabetic nephropathy
has been reported. Vasohibin-1 (VASH-1) is a unique endogenous
angiogenesis inhibitor that is induced in endothelial cells by
proangiogenic factors. We investigated the therapeutic efﬁcacy of
VASH-1 in an early diabetic nephropathy model.
RESEARCH DESIGN AND METHODS—Streptozotocin-
induced type 1 diabetic mice received intravenous injections of
adenoviral vectors encoding VASH-1 (AdhVASH-1) or -gal (Ad-
LacZ) every other week and were killed after 28 days.
RESULTS—Treatment with AdhVASH-1 resulted in sustained
increase in the protein levels of VASH-1 in the liver and sera, in
the absence of any inﬂammatory alterations. AdhVASH-1 treat-
ment signiﬁcantly suppressed renal hypertrophy, glomerular
hypertrophy, glomerular hyperﬁltration, albuminuria, increase of
the CD31
 glomerular endothelial area, F4/80
 monocyte/mac-
rophage inﬁltration, the accumulation of type IV collagen, and
mesangial matrix compared with AdLacZ-treated diabetic mice.
Increase in the renal levels of transforming growth factor-1,
monocyte chemoattractant protein-1, and receptor for advanced
glycation end products in diabetic animals was signiﬁcantly
suppressed by AdhVASH-1 (real-time PCR and immunoblot).
VASH-1 signiﬁcantly suppressed the increase of transforming
growth factor-, monocyte chemoattractant protein-1, and recep-
tor for advanced glycation end products, induced by high ambi-
ent glucose in cultured mouse mesangial cells. Increased
phosphorylation of VEGFR2 was suppressed in AdVASH-1–
treated diabetic animals and in cultured glomerular endothelial
cells. Endogenous mouse VASH-1 was localized to the mesangial
and endothelial area in glomeruli of diabetic mice.
CONCLUSIONS—These results suggest the potential therapeu-
tic efﬁcacy of VASH-1 in treating early diabetic nephropathy
potentially mediated via glomerular endothelial and mesangial
cells. Diabetes 58:2365–2375, 2009
D
iabetic nephropathy is a major microvascular
complication of type 1 and 2 diabetes, and
30–40% of patients with type 2 diabetes develop
diabetic nephropathy. Because diabetic ne-
phropathy is the most common pathological disorder
predisposing end-stage renal disease (ESRD) in Japan and
in the Western world, novel therapeutic approaches are
required. In the early stage of diabetic nephropathy, glo-
merular hyperﬁltration, glomerular and tubular epithelial
hypertrophy, microalbuminuria, and thickening of the
glomerular basement membrane are typically observed.
Expansion of the extracellular matrix (ECM) in mesangial
areas and overt proteinuria are observed, eventually lead-
ing to glomerulosclerosis and ESRD (1). The involvement
of various factors and cytokines including the renin-
angiotensin system, IGF-I, monocyte chemoattractant pro-
tein-1 (MCP-1), ﬁbrogenic transforming growth factor-1
(TGF-1), protein kinase C (PKC), and advanced glycation
end products (AGE) in diabetic nephropathy has been
reported (2,3).
Angiogenesis is associated with pathological conditions
including tumor growth and diabetic retinopathy (4).
Vascular endothelial growth factor (VEGF)-A, a potent
stimulator of angiogenesis, promotes endothelial cell
proliferation, migration, and tube formation (5), and in-
duces vascular permeability and inﬂammation (6).
Previous studies have demonstrated the increased glo-
merular ﬁltration surface in diabetic nephropathy resulting
from the formation of new glomerular capillaries and a
slight elongation of the preexisting capillaries (7,8), anal-
ogous to the changes in pathological diabetic retinopathy.
The increase in the levels of VEGF-A and the receptor of
VEGF-A, VEGFR2, has been reported in diabetic nephrop-
athy models (9,10). In addition, the therapeutic efﬁcacies
of anti–VEGF-A strategies (i.e., neutralizing antibodies and
a receptor tyrosine kinase inhibitor) have further demon-
strated the involvement of VEGF-A in the progression of
diabetic nephropathy (11–13).
The therapeutic effects of antiangiogenic reagents, tum-
statin peptide, endostatin peptide, angiostatin, pigment
epithelium–derived factor, and 2-(8-hydroxy-6-methoxy-1-
oxo-1h-2-benzopyran-3-yl) propionic acid (NM-3) (14–18)
in diabetic nephropathy models have been reported by
others and us.
Vasohibin-1 (VASH-1), an endogenous angiogenesis in-
hibitor, was identiﬁed from a microarray analysis to inves-
tigate genes upregulated by VEGF in endothelial cells (19).
The therapeutic effects of VASH-1 on tumor growth, ath-
erosclerosis, and proliferative retinopathy models have
been reported (19–21). Based on the unique characteris-
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FIG. 1. A: Immunoblot analysis. Immunoblot for human VASH-1 and actin are shown. Each lane was loaded with 50 g protein obtained from the
serum samples or liver. The AdhVASH-1–injected diabetic mice exhibited signiﬁcantly elevated serum VASH-1 (42 kDa) levels compared with the
AdLacZ-injected diabetic mice (4 weeks). Similarly, enhanced protein levels of VASH-1 in the liver were observed in AdhVASH-1–treated mice
compared with AdLacZ-treated diabetic mice. Immunoblots for actin are shown to conﬁrm equal loading. B: Increase in KW-to-BW ratio induced
by STZ was diminished in the AdhVASH-1–treated diabetic group. Kidney weight relative to body weight was determined before termination of
the experiments. C: Increase in UACR induced by STZ was signiﬁcantly suppressed by treatment with AdhVASH-1. Data obtained at 4 weeks after
initiating treatment with Ad-LacZ or AdhVASH-1 is shown. D: Increase in Ccr induced by STZ was partially suppressed by AdhVASH-1. B–D:* P <
0.05 versus N. †P < 0.05 versus Ve or LacZ. E–H: Representative light microscopic appearance of glomeruli (periodic acid-Schiff staining, original
magniﬁcation 400) for nondiabetic control mice (E) and diabetic mice treated with either vehicle buffer (F), AdLacZ (G), or AdhVASH-1 (H).
I: Increase in glomerular volume induced by STZ was diminished by treatment with AdhVASH-1. J: Mesangial matrix index was deﬁned as the
proportion of the glomerular tuft occupied by the mesangial matrix area (excluding nuclei). I and J:* P < 0.01 versus N. †P < 0.01 versus Ve or
LacZ; n  5 for each group. N, nondiabetic control; Ve, diabetic mice treated with vehicle buffer; LacZ, diabetic mice treated with AdLacZ (5 
10
9 vp/mice); Vas, diabetic mice treated with AdhVASH-1 (5  10
9 vp/mice). Each column consists of means  SE. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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endothelial cell–derived negative feedback regulator of
angiogenesis.
In the present study, we demonstrate the therapeutic
efﬁcacy of VASH-1 in ameliorating renal alterations in the
streptozotocin (STZ)-induced mouse type 1 diabetes
model. Treatment with adenoviral vector encoding human
VASH-1 (AdhVASH-1) markedly suppressed characteristic
alterations of early diabetic nephropathy. These effects
were associated with the regulation of VEGFR2 activation
in glomerular endothelial cells and of TGF-1, MCP-1, and
receptor for advanced glycosylation end product (RAGE)
in mesangial cells.
RESEARCH DESIGN AND METHODS
Adenoviral vectors. A replication-defective AdhVASH-1 was prepared as
previously described (19). A replication-defective adenovirus vector encoding
the Escherichia coli -galactosidase (AdLacZ), which is identical to Adh-
VASH-1 except for the inserted cDNA, was used as the control (19) (see the
online appendix available at http://diabetes.diabetesjournals.org/content/
early/2009/07/08/db08-1790/suppl/DC1).
Induction of diabetes and experimental protocols. The experimental
protocol was approved by the Animal Ethics Review Committee of Okayama
University. Male imprinting control region mice were fed a standard pellet
laboratory diet and were provided with water ad libitum. Type 1 diabetes was
induced by low-dose STZ injection as detailed by the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) Consortium for Animal
Models of Diabetic Complications’ (AMDCC) protocol (available from http://
www.amdcc.org) with modiﬁcation. Weight-matched 5-week-old male mice
received intraperitoneal injections of STZ (Sigma, St. Louis, MO; 120 mg/kg
body weight) dissolved in 10 mmol/l Sodium citrate, pH 5.5. Control mice
received injections with buffer alone. STZ or citrate buffer was administered
at three time points occurring at 48-h intervals during the ﬁrst week. Six days
after the third injection of STZ, mice with blood glucose in the range of
13.9–22.2 mmol/l were divided into four subgroups: 1) nondiabetic control
and diabetic mice treated with either, 2) vehicle buffer (saline), 3) AdLacZ, or
4) AdhVASH-1 (n  5 for each subgroup). Thirty-two mice received injections
of STZ, and 15 mice exhibiting hyperglycemia in the range as described above
were selected for experiments. At this point, intravenous injections of
adenoviral vectors (AdLacZ or AdhVASH-1) or saline (via tail veins) were
initiated using a syringe with a 27-gauge needle and were repeated every other
week (5  10
9 vp/100 l). Four weeks after the initial injections of adenoviral
vectors (6 weeks after the induction of diabetes), mice were killed and the
kidneys were obtained. No mice died and no signs of apparent exhaustion
were observed during the experimental period (available in an online
appendix).
Blood and urine examination. Blood glucose was measured in tail-vein
blood, and urine was tested for keton bodies and glucose by the OML
(Okayama Medical Laboratories, Okayama, Japan). Serum and urinary creat-
inine levels and urinary albumin concentration were determined as previously
described (14). Results were normalized to the urinary creatinine levels and
expressed as the urinary albumin-to-creatinine ratio (UACR). The creatinine
clearance (Ccr) was calculated and expressed as milliliters per minute per
100 g of body weight (available in an online appendix).
Histological analysis. Four weeks after starting treatment, kidneys were
removed, ﬁxed in 10% buffered formalin, and embedded in parafﬁn. Sections (3
m) were stained with periodic acid-Schiff for light microscopic observation
(available in an online appendix).
Immunohistochemistry. Immunohistochemistry was performed using fro-
zen sections as previously described (18,22–24) (available in an online
appendix).
RNA extraction and quantitative real-time PCR. RNA extraction and
real-time PCR were performed as previously described with modiﬁcations
(14,18) (available in an online appendix).
Immunoblot assay. Immunoblot assay was performed as previously de-
scribed (18,25) (available in an online appendix).
Recombinant VASH-1. Recombinant VASH-1 was prepared as previously
described (19). Human VASH-1 protein connected to the FLAG tag at the
C-terminus was expressed in a Bac-to-Bac baculovirus expression system
(Invitrogen) according to the manufacturer’s instructions and puriﬁed as a
soluble protein (19).
Cell culture. Primary murine mesangial cells (MES13) were utilized to
determine the direct effect of recombinant human VASH-1 on high glucose–
induced increase of the protein levels of TGF-, MCP-1, and RAGE as
previously described (18,26) (available in an online appendix). Primary human
glomerular microvascular endothelial cells (hGECs) were utilized to deter-
mine the direct effect of recombinant human VASH-1 on VEGF (R&D Systems)
or high glucose–induced increase of the phosphorylation of VEGFR2 (avail-
able in an online appendix).
Statistical analysis. All values are expressed as means  SE. A Kruskal-
Wallis with post hoc comparisons using the Scheffe’s test was employed for
inter-group comparisons of multiple variables. Statistical analysis was per-
formed by SPSS Software for Windows (version 13.0; Chicago, IL). A level of
P  0.05 was considered statistically signiﬁcant.
RESULTS
Serum and hepatic levels of VASH-1 after adenoviral
transfer. The serum levels of VASH-1 were at very low
levels in the nondiabetic mice (immunoblot). The Adh-
VASH-1–injected diabetic mice exhibited signiﬁcantly ele-
vated serum VASH-1 levels compared with the AdLacZ
injection at 4 weeks after the initial injections (Fig. 1A).
Similarly, hepatic expression of VASH-1 was markedly ele-
vated in the AdhVASH-1–injected diabetic mice (Fig. 1A). The
mice receiving AdLacZ or AdhVASH-1 did not exhibit any
deleterious side effects, and all the mice survived.
Nondiabetic male imprinting control region mice receiv-
ing AdhVASH-1 did not exhibit any inﬂammatory or patho-
logical alterations in the lungs, livers, or kidneys (data
not shown), and hypertension or proteinuria was not
observed.
Changes in blood glucose, body weight, and kidney
weight/body weight. Treatment with AdhVASH-1 did not
exhibit therapeutic effects on hyperglycemia (Table 1).
Body weight was signiﬁcantly lower in all of the diabetic
groups compared with nondiabetic animals, and Adh-
VASH-1 treatment did not signiﬁcantly inﬂuence body
weight. Diabetic animals exhibited a signiﬁcantly greater
kidney weight-to-body weight (KW-to-BW) ratio compared
with nondiabetic mice (Fig. 1B). Injection of AdhVASH-1
resulted in a signiﬁcantly decreased KW-to-BW ratio com-
pared with the control diabetic mice (Fig. 1B).
Changes in blood pressure. There were no signiﬁcant
differences in blood pressure among nondiabetic animals,
diabetic mice, and diabetic mice treated with adenoviral
vectors (Table 1).
Changes in serum creatinine, Ccr, and urinary albu-
min excretion. Serum creatinine levels did not signiﬁcantly
differ among the experimental groups. Although control
diabetic mice showed a marked elevation of the Ccr and
UACR, AdhVASH-1 suppressed STZ-induced increase of Ccr
and UACR (Fig. 1C and D).
Histology and morphometric analysis. Glomerular hy-
pertrophy and mesangial matrix expansion were signiﬁ-
cantly inhibited by AdhVASH-1 compared with the control
diabetic animals (Fig. 1E–H). Morphometric analysis (Fig.
TABLE 1
Body weight, blood glucose concentration, and blood pressure
Body
weight (g)
Blood
glucose
(mmol/l)
MBP
(mmHg)
Nondiabetic 35.8  0.2 7.3  0.3 80.6  3.0
Diabetic (vehicle) 30.8  1.8* 27.3  0.7* 80.9  1.7
Diabetic (AdLacZ) 31.6  2.1* 27.6  1.2* 78.9  2.6
Diabetic (AdhVASH-1) 30.6  0.6* 27.8  0.9* 80.3  2.0
*P  0.05 vs. nondiabetic animals. Values are shown as means SE;
n  5 in each group. Vehicle, vehicle buffer treated; MBP, mean
blood pressure.
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AdhVASH-1 on these parameters.
Immunohistochemical analysis of CD31
 endothelial
area. We next evaluated differences in the amount of the
CD31
 glomerular endothelial area by immunoﬂuores-
cence staining. In nondiabetic mice, CD31 was detected
in glomerular capillaries (Fig. 2A), and increase of the
CD31
 area in glomeruli was observed in control dia-
betic mice (Fig. 2B and C). Treatment with AdhVASH-1
markedly suppressed the increase of the glomerular
CD31
 area (Fig. 2D). Quantitative analysis (Fig. 2E)
further conﬁrmed that the STZ-induced increase in the
glomerular capillary area was signiﬁcantly suppressed
by AdhVASH-1. We evaluated the CD31
 peritubular
capillary (PTC) endothelial area to determine the poten-
tial adverse effects of VASH-1 on the survival of PTC. In
the control diabetic mice, a slight increase of PTC
density was observed, and AdhVASH-1 did not signiﬁ-
cantly inﬂuence the PTC density (supplemental Fig. 1,
available in an online appendix).
Protein levels of VEGF-A and receptor VEGFR2 in
renal cortex. The effect of AdhVASH-1 on the expression
of proangiogenic factor VEGF-A and corresponding recep-
tors VEGFR2 in the renal cortex was studied by immuno-
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FIG. 2. A-E: Immunoﬂuorescent staining of CD31, an endothelial cell
marker. Distribution of CD31 was determined by indirect immunoﬂuores-
cence technique in nondiabetic control mice (A) and diabetic mice treated
with either vehicle buffer (B), AdLacZ (C), or AdhVASH-1 (D). E: Glomer-
ular CD31
 endothelial area was quantitated. Increase in the CD31
 glomer-
ular capillary area was signiﬁcantly suppressed after treatment with
AdhVASH-1. *P < 0.01 versus N. †P < 0.01 versus Ve or LacZ. F and G:
Immunoblot analysis. Immunoblots for VEGF-A, phosphorylated VEGFR2
(pVEGFR2), total VEGFR2, and actin are shown. Each lane was loaded with
50 g protein obtained from the renal cortex. Each band was scanned and
subjected to densitometry. F (lower panels): Intensities of VEGF-A protein
relative to actin are shown. *P < 0.01 versus N. H and I: Intensities of
pVEGFR2 relative to total VEGFR2 (upper graph) and those of VEGFR2
relative to actin (lower graph) are shown. *P < 0.01 versus N. †P < 0.05
versus Ve or LacZ; n  5 for each group. (A high-quality digital representa-
tion of this ﬁgure is available in the online issue.)
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signiﬁcantly increased in the control diabetic mice, which
is consistent with previous reports (9,15). Treatment with
AdhVASH-1 did not affect the STZ-induced increase of
VEGF-A but signiﬁcantly suppressed the increase of
VEGFR2 compared with AdLacZ (Fig. 2F–H).
Phosphorylation of VEGFR2 in vivo and in cultured
hGECs. Next, we examined the potential inhibitory effects
of VASH-1 on phosphorylation of VEGFR2. The ratio of
phosphorylated VEGFR2 relative to total VEGFR2 in renal
cortex of control diabetic mice was elevated compared
with nondiabetic animals, and AdhVASH-1 treatment
showed inhibitory effects (Fig. 2G and I). We performed
cell culture analysis using hGECs. The ratio of phosphor-
ylated VEGFR2 relative to total VEGFR2 in hGECs was
signiﬁcantly increased at 2–15 min after initiating stimula-
tion with 1 nmol/l VEGF compared with control as de-
tected by immunoblots (Fig. 3A). Because the peak of
pVEGFR2-to-VEGFR2 ratio was observed at 5 min after
stimulation with VEGF, we performed subsequent exper-
iments under this condition. Increase in the levels of
pVEGFR2-to-VEGFR2 ratio was signiﬁcantly suppressed
by recombinant VASH-1 as detected by immunoblots (Fig.
3B). Similarly, the level of pVEGFR2-to-VEGFR2 ratio in
hGECs was signiﬁcantly increased at 24 h after incubation
in medium supplemented with 25 mmol/l glucose (high
glucose) compared with incubation under the normal
glucose condition (normal glucose) as detected by immu-
noblots (Fig. 3C). Addition of mannitol to the culture
condition under normal glucose did not lead to the signif-
icant increase of pVEGFR2-to-VEGFR2 ratio, thus exclud-
ing the potential effect caused by elevated osmotic
pressure. Treatment with recombinant VASH-1 resulted in
the suppression of the increase of pVEGFR2-to-VEGFR2
ratio induced by high glucose in a dose-dependent manner
(Fig. 3C).
Immunohistochemical analysis of glomerular type IV
collagen. Next, the accumulation of glomerular type IV
collagen was examined by immunoﬂuorescence staining
(Fig. 4). The amount of type IV collagen in glomeruli was
increased in the control diabetic group (Fig. 4B and C)
compared with the nondiabetic mice (Fig. 4A). Enhanced
immunoreactivity in the diabetic mice was observed mainly
in the glomerular basement membrane and mesangial area.
Treatment with AdhVASH-1 decreased the accumulation of
type IV collagen induced by STZ compared with AdLacZ
treatment (Fig. 4D), and these results were further conﬁrmed
by quantitative morphometric analysis (Fig. 4G).
Immunohistochemical analysis of monocyte/macro-
phage inﬁltration. We examined glomerular inﬁltration
of monocytes/macrophages by immunohistochemistry for
F4/80. In the control diabetic mice, the number of F4/
80() cells was signiﬁcantly increased compared with the
nondiabetic mice. Treatment with AdhVASH-1 markedly
decreased the accumulation of monocytes/macrophages in
glomeruli (Fig. 4H).
Protein and mRNA levels of TGF-1 in renal cortex.
TGF-1 is a proﬁbrotic factor involved in mesangial
matrix expansion and renal hypertrophy in diabetic
nephropathy (27). The control diabetic mice exhibited
increased levels of TGF- protein compared with the
nondiabetic animals in the renal cortex (immunoblots).
AdhVASH-1 signiﬁcantly suppressed the increase of
TGF- in the diabetic animals compared with AdLacZ
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FIG. 3. A-C: Immunoblot analysis (cultured hGECs). Immunoblots for
pVEGFR2, VEGFR2, and actin are shown. A: Cells were stimulated with
1 nmol/l of VEGF for 2–15 min. Intensities of pVEGFR2 protein relative
to total VEGFR2 are shown. *P < 0.01 versus control (0). B: Cells were
stimulated with 1 nmol/l of VEGF for 5 min in the presence of
recombinant VASH-1 (0–20 nmol/l). Intensities of pVEGFR2 protein
relative to VEGFR2 are shown. *P < 0.01 versus control. †P < 0.05
versus VEGF()/VASH-1(0). C: Cells were cultured under normal
glucose (5.5 mmol/l) or high glucose (25 mmol/l) for 24 h in the
presence of recombinant VASH-1 (0–20 nmol/l). Intensities of
pVEGFR2 protein relative to VEGFR2 are shown. *P < 0.01 versus
normal glucose or normal glucose/Manni. †P < 0.05 versus high glucose/
V0. Each lane was loaded with 15 g protein obtained from hGECs.
Normal glucoseManni, normal D-glucose plus D-mannitol (19.5 mmol/
l); V0, without VASH-1; V1, 1 nmol/l VASH-1; V10, 10 nmol/l VASH-1;
V20, 20 nmol/l VASH-1.
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VASH-1 on the levels of TGF-1 mRNA were observed
by real-time PCR (Fig. 5C).
Protein and mRNA levels of MCP-1 in renal cortex.
MCP-1 is one of the crucial chemokines involved in the
development of diabetic nephropathy (28). Control dia-
betic mice exhibited increased levels of MCP-1 protein
compared with nondiabetic animals in the renal cortex
(immunoblot). Treatment with AdhVASH-1 resulted in the
suppression of MCP-1 protein levels compared with Ad-
LacZ (Fig. 5D and E). Similar inhibitory effects of Adh-
VASH-1 on the increase of the mRNA levels of MCP-1 in
diabetic animals were observed (Fig. 5F).
Protein levels of RAGE in renal cortex. The potential
role of AGE in the pathogenesis of diabetic nephropathy
has been reported (29). RAGE, a well-characterized cell
surface receptor for AGE, plays an important role in the
development of diabetic nephropathy (30). The control
diabetic mice exhibited increased protein levels of RAGE
compared with nondiabetic animals in the renal cortex
(immunoblots). Treatment with AdhVASH-1 resulted in
the suppression of RAGE protein levels compared with
AdLacZ treatment (Fig. 5G and H).
Protein levels of TGF-, MCP-1, and RAGE in cul-
tured mouse mesangial cells. To examine the potential
direct effects of VASH-1 on nonendothelial cells in associ-
ation with the observed therapeutic effects in vivo, we
performed cell culture analysis using primary mouse
mesangial cells. The protein level of TGF-, MCP-1, and
RAGE in mesangial cells was signiﬁcantly increased at
48 h after incubation in high glucose condition com-
pared with incubation under normal glucose condition
as detected by immunoblots (Fig. 6). Addition of man-
nitol to the normal glucose condition did not lead to the
increase of TGF-, MCP-1, and RAGE, thus excluding
the potential effect by elevated osmotic pressure. Treat-
ment with recombinant VASH-1 resulted in the suppres-
sion of the increase of protein levels for TGF-, MCP-1,
and RAGE induced by high glucose in a dose-dependent
manner (Fig. 6).
Localization and the levels of endogenous mouse
VASH-1 in kidney. In nondiabetic mice, endogenous
mouse VASH-1 (mVASH-1) was observed in arterioles and
in glomeruli. Immunoreactivity for mVASH-1 was in-
creased in diabetic glomeruli, and was remarkable in the
mesangial (-SMA
) area and in endothelial (CD31
) area
as detected by double immunoﬂuorescent staining (Fig. 7A
and B). In blood vessels, mVASH-1 was mainly localized to
the outer aspect of vessels, presumably in smooth muscle
cells (-SMA
) and in the adventitia, and slightly observed
in the endothelium (CD31
) as well (Fig. 7A and B).
Immunoblot analysis revealed a mild increase of renal
endogenous mVASH-1 in the vehicle-treated diabetic mice
compared with the nondiabetic control mice without
statistically signiﬁcant difference (Fig. 2, available in an
online appendix). Treatment with AdhVASH-1 did not alter
the levels of endogenous mVASH-1 compared with the
control diabetic mice.
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FIG. 4. A–D: Glomerular accumulation of type IV collagen was assessed by the indirect immunoﬂuorescence method for nondiabetic control mice
(A) and diabetic mice treated with either vehicle buffer (B), AdLacZ (C), or AdhVASH-1 (D). A–D: Original magniﬁcation 200. E and F:
Immunohistochemistry of F4/80
 monocyte/macrophage. Representative light microscopic appearances of glomerulus in diabetic mice treated
with vehicle buffer stained in the presence of the primary antibodies (E) or normal rat IgG (F) are shown. F4/80
 cells were observed in diabetic
mice (arrowheads; original magniﬁcation 400). G: The amount of immunoreactive type IV collagen in glomeruli relative to the nondiabetic
control group determined by computer image analysis is shown. H: The number of glomerular F4/80
 monocyte/macrophages is shown. Increase
in the F4/80
 monocyte/macrophage number was signiﬁcantly suppressed after treatment with AdhVASH-1; n  5 for each group. *P < 0.01 versus
N. †P < 0.01 versus Ve or LacZ. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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In the present study, we utilized a STZ-induced type 1
diabetes mouse model to demonstrate the therapeutic
efﬁcacy of VASH-1. Although renal failure is not easily
reproducible, some of the characteristic early alterations
in human diabetic nephropathy such as albuminuria, glo-
merular hyperﬁltration, and some of the characteristic
histopathologic changes can be observed in this model
(31). Intravenous administration of AdhVASH-1 resulted in
the sustained increase of serum levels of hVASH-1 presum-
ably derived from liver, without causing any systemic
inﬂammatory reactions. Additionally, administration of
AdhVASH-1 in nondiabetic mice did not cause any inﬂam-
matory histological alterations in the kidney. Therefore,
we consider the present approach using adenoviral vec-
tors as nonharmful for experimental animals. Treatment
with AdhVASH-1 did not affect hyperglycemia or body
weight loss induced by STZ, similar to our previous
observations using antiangiogenic tumstatin peptide and
endostatin peptide (14,15). Although diabetic mice exhib-
ited signiﬁcant weight loss, the extent of reduced body
weight was comparable to previous reports utilizing this
model. In the control diabetic mice, characteristic alter-
ations in early diabetic nephropathy such as albuminuria,
glomerular hypertrophy, glomerular hyperﬁltration as ev-
idenced by increased Ccr, and renal hypertrophy were
observed. These early abnormalities in diabetic nephrop-
athy were signiﬁcantly inhibited by AdhVASH-1 compared
with AdLacZ treatment. Histological assessment demon-
strated that treatment with AdhVASH-1 suppressed the
increase of the CD31
 glomerular endothelial area in
diabetic mice. Experimental diabetic animals exhibit an
increased glomerular ﬁltration surface area as well as
glomerular capillary number in the early stage of the
disease (7,8). AdhVASH-1 treatment has suppressed these
alterations potentially via the antiangiogenic efﬁcacy, lead-
ing to the observed therapeutic effects on the increase of
Ccr and albuminuria.
In the present study, the level of VEGF-A was increased
in the renal cortex of diabetic mice, consistent with
previous studies (9,10,14). Recent reports have demon-
strated reduced expression of VEGF-A in human diabetic
nephropathy patients (32,33). Although diabetic animal
models are often studied in a relatively early phase of the
disease, most diabetic patients used in clinical studies
were already in a moderately advanced stage. For in-
stance, reduced VEGF expression in the renal interstitium
was associated with interstitial vascular rarefaction in a
study using samples of human diabetic nephropathy (33),
but we could not detect a reduction of PTC density in the
present study in the control diabetic animals. Treatment
with AdhVASH-1 did not diminish the increase of VEGF-A
in the renal cortex but resulted in the suppression of the
increase of VEGFR2. The regulatory role of VASH-1 on
VEGFR2 but not VEGF-A is consistent with previous
results on proliferative retinopathy (21). In addition,
VASH-1 signiﬁcantly suppressed the increase of pVEGFR2-
to-VEGFR2 ratio in diabetic animals as well as in cultured
glomerular endothelial cells. Our results are not consistent
with previous reports demonstrating that VASH-1 did not
inhibit VEGF-induced VEGFR2 phosphorylation in human
umbilical vein endothelial cells (19). Unique characteris-
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FIG. 5. Immunoblot analysis and real-time PCR of
TGF-, MCP-1, and RAGE. A, D, and G: Immuno-
blots for TGF-, MCP-1, RAGE, and actin are
shown. Each lane was loaded with 50 g protein
obtained from the renal cortex. B: Intensities of
TGF- protein relative to actin are shown. E: In-
tensities of MCP-1 protein relative to actin are
shown. H: Intensities of RAGE protein relative to
actin are shown. C and F: The levels of TGF-1
mRNA and MCP-1 mRNA detected by real-time
PCR. Total RNA was extracted from the renal
cortex and subjected to the examination using
quantitative real-time PCR. C: The amount of
TGF-1 mRNA relative to 18s rRNA is shown. Re-
sults are expressed relative to nondiabetic control
mice that were arbitrarily assigned a value of 1.0. F:
The amount of MCP-1 mRNA relative to GAPDH is
shown. B, C, E, F, and H:* P < 0.01 versus N. †P <
0.05 versus Ve or LacZ; n  5 for each group.
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tration are well known, and such differences among
distinct endothelial cell types may underlie the discrepant
response to VASH-1 concerning VEGFR-2 phosphoryla-
tion. The therapeutic effect of VASH-1 in early diabetic
nephropathy, at least in part, may be attributed to the
inhibition of overactivation of the VEGF-A pathway in
analogy with previous studies utilizing neutralizing anti-
VEGF-A antibodies (11,12) and a recent report demon-
strating that inducible overexpression of soluble ﬂt-1
(VEGFR1), an antagonist of VEGF-A, in podocytes amelio-
rated diabetic glomerular alterations in mice (34). To date,
cell surface receptors for VASH-1 as well as potential
inﬂuence of VASH-1 on intracellular signal transduction
have not been fully identiﬁed, and future analysis on
crosstalk between VASH-1 signaling and VEGF signaling is
required.
We observed a signiﬁcant inhibitory effect of Adh-
VASH-1 on renal hypertrophy in diabetic mice. VEGF-A
augments protein synthesis and hypertrophy in renal prox-
imal tubular epithelial cells (35). Considering the domi-
nant contribution of the tubular compartment in
organizing renal mass, we speculate that AdhVASH-1
might have affected the tubular hypertrophy potentially via
regulating VEGF-A–mediated signaling.
In the present study, increase in the levels of renal
TGF- was signiﬁcantly suppressed by AdhVASH-1, poten-
tially associated with therapeutic efﬁcacy on the accumu-
lation of ECM. These results are consistent with previous
reports demonstrating the inhibitory effects of antiangio-
genic reagents on ECM accumulation in animal models of
diabetic nephropathy (14–16,18,36).
Interestingly, recombinant VASH-1 treatment resulted in
the suppression of the increase of TGF- induced by high
glucose in cultured mesangial cells. We previously ob-
served similar inhibitory effects of NM-3 on high glucose–
induced TGF- production in mesangial cells (18),
suggesting the novel potential therapeutic mechanisms of
antiangiogenic factors mediated via direct interaction with
‘nonendothelial’ mesangial cells.
A recent report has demonstrated the potential role of
VEGF in mediating glomerular monocyte/macrophage in-
ﬁltration in a diabetic animal model (37). Therefore,
observed anti-inﬂammatory effect of VASH-1 might be, at
least in part, associated with regulation of vascular per-
meability. Yamashita et al. (20) have demonstrated the
therapeutic role of AdhVASH-1 in preventing arterial neo-
intimal formation. Adventitial macrophage inﬁltration was
inhibited by AdhVASH-1 (20), similar to our present re-
sults. In addition, VASH-1 suppressed renal MCP-1 expres-
sion in diabetic animals and suppressed the increase of
MCP-1 induced by high glucose in cultured mesangial
cells. The inhibitory effect of AdhVASH-1 on the increase
of chemokines may also mediate its anti-inﬂammatory
effects. Previous reports have demonstrated the associa-
tion between inﬁltration of macrophages and the accumu-
lation of ECM proteins in the mesangium in diabetic
models (38,39). Regarding the source of TGF-, macro-
phages as well as mesangial cells can secrete TGF- (40).
Thus, we speculate that the observed regulatory effects of
VASH-1 on the accumulation of monocytes/macrophages
might have contributed to the inhibition of mesangial
matrix accumulation.
The deleterious effects of AGE in the development of
diabetic nephropathy and the therapeutic effects of AGE
inhibitors in preventing the progression of experimental
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FIG. 6. A-E: Immunoblot analysis (cultured mesangial cells). A and D:
Immunoblots for MCP-1, TGF-, RAGE, and actin are shown. Each lane
was loaded with 20 g protein obtained from mouse mesangial cells. B:
Intensities of MCP-1 protein relative to actin are shown. *P < 0.05
versus normal glucose (NG) or normal glucose/Manni. †P < 0.05 versus
high glucose (HG)/V0. ‡P < 0.05 versus high glucose/V1. C: Intensities
of TGF- protein relative to actin are shown. *P < 0.05 versus normal
glucose or normal glucose/Manni. †P < 0.05 versus high glucose/V0 or
high glucose/V1. E: Intensities of RAGE protein relative to actin are
shown. *P < 0.05 versus normal glucose or normal glucose/Manni. †P <
0.05 versus high glucose/V0. ‡P < 0.05 versus high glucose/V1.
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AGE induces overexpression of TGF-, MCP-1, and VEGF
in cultured mesangial cells (42,43). Interaction of AGE
with RAGE plays an important role in diabetic nephropa-
thy (44). VASH-1 signiﬁcantly suppressed renal RAGE
levels in diabetic mice and suppressed the increase of
RAGE induced by high glucose in cultured mesangial cells.
These results suggest that antiﬁbrotic and anti-inﬂamma-
tory effects of VASH-1 were partially mediated via down-
regulating RAGE levels in mesangial cells, resulting in the
suppression of TGF- and MCP-1.
Regarding endogenous levels and localization of
mVASH-1, renal protein levels of mVASH-1 were mildly
increased in diabetic control mice. AdhVASH-1 did not
alter renal mVASH-1 levels compared with AdLacZ treat-
ment. In diabetic mice, mVASH-1 was observed in the
glomerular endothelium and mesangial area. Previous
reports have revealed the localization of human VASH-1 in
endothelium of the placenta, endometria, brain, athero-
sclerotic lesions, and choroidal neovascular membranes
(19,20,45,46). mVASH-1 was expressed in the retinal endo-
thelial cells in mice with ischemic retinopathy (21). The
localization of mVASH-1 in the mesangial area suggests
the synthesis of VASH-1 in mesangial cells, but also the
potential mesangial deposition of VASH-1 released from
endothelial cells could not be excluded. Studies using
VASH-1–deﬁcient mice (47) may clarify biological roles of
endogenous mVASH-1 in diabetic nephropathy in future.
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FIG. 7. Double immunoﬂuorescent staining for endogenous mVASH-1, CD31, and -SMA. A: Double immunoﬂuorescent staining of mVASH-1
(green), CD31 (red), and merged images in the kidney from nondiabetic (upper panels) or diabetic (lower panels) mice. Although mVASH-1 was
faintly observed in nondiabetic glomeruli, increased immunoreactivity for mVASH-1 was observed and partially colocalized with the CD31

endothelial cells (arrowheads) in the control diabetic mice. B: Double immunoﬂuorescent staining of mVASH-1 (green), -SMA (red), and merged
images in the kidney from nondiabetic mice (upper panels) or control diabetic animals (lower panels). In the nondiabetic kidney, immunore-
activity for -SMA was observed in extraglomerular arterioles colocalized with mVASH-1 (arrows). Immunoreactivity of mVASH-1 partially
colocalized with the -SMA
 mesangial cells (arrowheads) in the control diabetic mice. Original magniﬁcation 400. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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Systemic administration of antiangiogenic reagents may
lead to reduced angiogenic response in a setting requiring
neovessel formation such as myocardial infarction and
limb ischemia, pathological conditions complicated in
advanced diabetic patients. Neointimal formation is the
crucial cause of luminal narrowing of arteries in athero-
sclerosis. Although further assessment in the advanced
stage is required, AdhVASH-1 might be tolerable or even
therapeutic for atherosclerotic conditions considering a
previous report showing the therapeutic effects of Adh-
VASH-1 in preventing neointimal formation (20). The cru-
cial involvement of chronic hypoxia in association with
reduction of PTC in progressing tubulointertstitial injuries
has been reported (48). AdhVASH-1 did not reduce PTC
density in the present model, suggesting its safety in
diabetic nephropathy. However, careful evaluation on the
potential inﬂuence of VASH-1 on PTC density in advanced
diabetic nephropathy might be required.
Considering application to diabetic patients, potential
adverse events accompanied by the injection of adenoviral
vectors such as nonspeciﬁc inﬂammatory reactions and
the replication of adenoviruses in vivo should be avoided,
and further assessments on the safety of this strategy are
required.
Recently, Eremina et al. (49) have demonstrated the
potential adverse events of bevacizumab, a humanized
monoclonal antibody against VEGF, resulting in throm-
botic microangiopathy in patients with cancer. Consider-
ing the lack of such histological alterations in previous
experimental studies using anti-VEGF antibodies or
SU5416 (11–13), anti-VEGF therapy might not be detrimen-
tal for patients with diabetic nephropathy. More recently,
Ku et al. (34) have demonstrated that inducible podocyte-
speciﬁc overexpression of sVEGFR1 in adult mice amelio-
rated diabetic glomerular alterations, suggesting the
involvement of VEGF-A in diabetic nephropathy. Although
VASH-1 suppresses overactivation of VEGFR2, it does not
serve as a speciﬁc inhibitor of VEGF signaling (19). In
addition, AdhVASH-1 did not cause proteinuria in non-
diabetic mice. Thus, VASH-1 treatment is distinct from
strategies with speciﬁc inhibition of VEGF potentially
associated with less adverse events.
In conclusion, we demonstrated that VASH-1 effectively
ameliorated alterations in an animal model of early dia-
betic nephropathy. Our results demonstrate the direct
effects of VASH-1 on glomerular endothelial and mesangial
cells in association with antiangiogenic, antiﬁbrotic, and
anti-inﬂammatory mechanisms and regulatory effects on
RAGE-mediated pathways. We believe that our present
study will eventually guide us to the development of
novel therapeutic strategies for patients with diabetic
nephropathy.
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